Luncheon with the Experts — Carcinoid and Neuroendocrine Tumor Patients Are Invited!!

The Big Apple Noids support group has initiated and is sponsoring, in collaboration with the Carcinoid Cancer Foundation, Luncheon with the Experts, a program which brings together carcinoid and neuroendocrine tumor (NET) patients with physicians…

Treating Neuroendocrine Tumors: New Patent Awarded

Herbert Chen, MD, and Muthusamy Kunnimalaiyaan, Ph.D., of the University of Wisconsin School of Medicine and Public Health in Madison, have received a patent (8,338,482) for a “Modulating Notch1 Signaling Pathway for Treating Neuroendocrine…

Happy New Year from the Carcinoid Cancer Foundation

As 2012 draws to a close, the Carcinoid Cancer Foundation would like to thank each of you for your support.  This year has been especially exciting because of our work on the Worldwide NET Cancer Awareness Day Alliance, with Grace Goldstein, CCF’s Chief…

New Videos in Carcinoid Cancer Foundation 2012-2013 Series

Faces of Hope and Surgery and Treatment Options are the newest videos in the Carcinoid Cancer Foundation’s 2012-2013 series.  Awareness and education are the first critical components in the fight against carcinoid and NET (neuroendocrine …

10 Highlights of the Year 2012 for the Carcinoid and Neuroendocrine Tumor Community

As the Carcinoid Cancer Foundation looks back on the year 2012, there were many significant events and advances for the carcinoid and neuroendocrine tumor (NET) community.  Here are 10 of the year’s important stories:

1)       NET Cancer Day, November …

“Sunny Susan” Anderson Wins 2012 Warner Advocacy Award

When “Sunny Susan” Anderson began her search on the Internet in 1995 for information about carcinoid cancer little did she realize that she would later create the first carcinoid patient website and become an extraordinary advocate for others seeking…

Lexicon Pharmaceuticals Begins Phase 3 Clinical Trial of Telotristat Etiprate in Patients with Carcinoid Syndrome

Patients with metastatic carcinoid syndrome will have the opportunity to participate in a new Phase 3 clinical trial of Lexicon Pharmaceutical’s telotristat etiprate (LX1032), an oral drug candidate designed to treat carcinoid syndrome by reducing…

NETumor Humor Benefit

“If you’re laughing about it, you’re talking about it.”  Comedic performances by Greg Fitzsimmons, Frangela, Adam Ray, Andie Bolt, Eliana Horeczko, Fortune Feimster and more will be featured during the NEtTumor Humor Benefit at the Westside…

Carcinoid Cancer Foundation Participates in #GivingTuesday

Help launch #GivingTuesday™!!  The Carcinoid Cancer Foundation is proud to participate in the first annual #GivingTuesday™ to be held on Tuesday, November 27, 2102. Charities, families, businesses and individuals are coming together to transform…

First U.S. Center to Enroll Patients in International, Multicenter Clinical Trial of Lu-177 Octreotate

Excel Diagnostics and Nuclear Oncology Center in Houston, Texas, is the first center in the United States to start recruiting patients in a multicenter randomized clinical trial of Lu-177 Octreotate in patients with progressive midgut carcinoid. …